The most recent researches have revealed that activation of the HIF-1α pathway and glucose metabolism reprogramming play a crucial role in lenvatinib resistance in HCC [54, 55], both of which are intricately linked to PFKFB4. Here, HIF1A is linked to hepatocellular carcinoma.